These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 9248959)

  • 1. Susceptibility testing of fungi and correlation with clinical outcome.
    Ghannoum MA
    J Chemother; 1997 May; 9 Suppl 1():19-24. PubMed ID: 9248959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifungal susceptibility testing of yeasts: uses and limitations.
    Reyes G; Ghannoum MA
    Drug Resist Updat; 2000 Feb; 3(1):14-19. PubMed ID: 11498361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utility of in vitro antifungal susceptibility testing.
    Espinel-Ingroff A
    Rev Esp Quimioter; 2000 Jun; 13(2):161-6. PubMed ID: 10918088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Correlation between in vitro susceptibility to antifungal drugs and the clinical evolution of patients with candidiasis and cryptococcosis].
    Viudes A; Cantón E; Pemán J; López-Ribot JL; Gobernado M
    Rev Esp Quimioter; 2002 Mar; 15(1):32-42. PubMed ID: 12582435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on clinical antifungal susceptibility testing for Candida species.
    Lewis RE; Klepser ME; Pfaller MA
    Pharmacotherapy; 1998; 18(3):509-15. PubMed ID: 9620102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
    Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
    Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of antifungal susceptibility testing in patient management.
    Forrest G
    Curr Opin Infect Dis; 2006 Dec; 19(6):538-43. PubMed ID: 17075328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy.
    Antoniadou A; Torres HA; Lewis RE; Thornby J; Bodey GP; Tarrand JP; Han XY; Rolston KV; Safdar A; Raad II; Kontoyiannis DP
    Medicine (Baltimore); 2003 Sep; 82(5):309-21. PubMed ID: 14530780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Multicenter study of fungemia due to yeasts in Argentina].
    Rodero L; Davel G; Soria M; Vivot W; Córdoba S; Canteros CE; Saporiti A;
    Rev Argent Microbiol; 2005; 37(4):189-95. PubMed ID: 16502638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evaluation of a dried commercially prepared microdilution panel for antifungal susceptibility testing of five antifungal agents against Candida spp. and Cryptococcus neoformans.
    Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
    Diagn Microbiol Infect Dis; 2004 Oct; 50(2):113-7. PubMed ID: 15474320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal susceptibility testing of fluconazole by flow cytometry correlates with clinical outcome.
    Wenisch C; Moore CB; Krause R; Presterl E; Pichna P; Denning DW
    J Clin Microbiol; 2001 Jul; 39(7):2458-62. PubMed ID: 11427554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibilities to yeasts using the ATB FUNGUS 2 method, compared with Sensititre Yeast One and standard CLSI (NCCLS) M27-A2 methods.
    Torres-Rodríguez JM; Alvarado-Ramírez E
    J Antimicrob Chemother; 2007 Sep; 60(3):658-61. PubMed ID: 17623690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifungal susceptibility of Cryptococcus neoformans isolates in HIV-infected patients to fluconazole, itraconazole and voriconazole in Spain: 1994-1996 and 1997-2005.
    Aller AI; Claro R; Castro C; Serrano C; Colom MF; Martín-Mazuelos E
    Chemotherapy; 2007; 53(4):300-5. PubMed ID: 17496416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifungal susceptibility testing: progress and future developments.
    Pfaller MA
    Braz J Infect Dis; 2000 Apr; 4(2):55-60. PubMed ID: 11012296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluconazole and itraconazole susceptibility of clinical isolates of Cryptococcus neoformans at a tertiary care centre in India: a need for care.
    Datta K; Jain N; Sethi S; Rattan A; Casadevall A; Banerjee U
    J Antimicrob Chemother; 2003 Oct; 52(4):683-6. PubMed ID: 12951350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of the susceptibility of yeast isolates of clinical interest to five antifungal agents using the E test.
    Linares MJ; Muñoz JF; Solís F; Rodríguez FC; Valero A; Casal M
    Rev Esp Quimioter; 1998 Mar; 11(1):64-9. PubMed ID: 9795292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of antifungal resistance.
    Espinel-Ingroff A
    Infect Dis Clin North Am; 1997 Dec; 11(4):929-44. PubMed ID: 9421708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro antifungal susceptibility testing.
    Hoffman HL; Pfaller MA
    Pharmacotherapy; 2001 Aug; 21(8 Pt 2):111S-123S. PubMed ID: 11501985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs.
    Abdel-Salam HA
    Mycoses; 2005 Sep; 48(5):327-32. PubMed ID: 16115103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of antifungal drugs and their use for treatment of deep and superficial mycoses in animals.
    Hector RF
    Clin Tech Small Anim Pract; 2005 Nov; 20(4):240-9. PubMed ID: 16317914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.